Huahui, BeOne Expand Oncology Pipeline with HH160 Deal

Huahui Health announced that it has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a novel trispecific antibody in oncology immunotherapy. Under the agreement, BeOne Medicines is granted an exclusive option covering the development, manufacturing, and commercialization of HH160 worldwide.

Dr. Chen Bin, CEO of Huahui Health, stated, "Huahui Health has established an integrated research and development engine covering the full drug development value chain, enabling the independent identification of novel targets and development of proprietary drug candidates. Our pipeline includes one marketed product and several clinical-stage programs in Phase II, reflecting strong industry recognition of our R&D capabilities. BeOne Medicines is distinguished by its outstanding innovation capacity and global development expertise. We are delighted to deepen our collaboration with BeOne Medicines to advance HH160, a novel trispecific antibody for cancer immunotherapy, and to bring innovative immuno-oncology treatments to patients worldwide as early as possible."

Going forward, Huahui Health will leverage its robust in-house innovation platforms and full-chain R&D strengths to advance first-in-class and best-in-class candidates across liver diseases and oncology. Backed by a rich layered pipeline spanning preclinical to clinical stages, the company demonstrates outstanding independent innovation and sustainable capacity to deliver original novel drugs worldwide.